Immuron sales reach $7.7 million in FY26
Immuron (ASX:IMC) reported global sales of $7.7 million for FY26, marking a 6% increase over the prior comparative period.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Immuron (ASX:IMC) reported global sales of $7.7 million for FY26, marking a 6% increase over the prior comparative period.
Cyclopharm (ASX:CYC) executed an agreement with University Hospitals to install its Technegas system across 11 clinical locations.
Immutep (ASX:IMM) has secured United States patent number 12,673,088 for its cancer immunotherapy combination treatments.
Mesoblast (ASX:MSB) has treated 300 patients in a key clinical trial to validate a new low back pain therapy.
Pacific Edge (ASX:PEB) announced that its Asia Pacific business is advancing towards profitability on a direct-cost basis.
Ryman Healthcare (ASX:RYM) reported 325 sales of retirement living occupation right agreements for the quarter ended June 30.
OncoSil Medical (ASX:OSL) completed three manufacturing validation cycles to establish a local production capability for over 50 device doses.
Regis Healthcare (ASX:REG) announced that CFO Rick Rostolis will retire from his position effective Aug. 31.
Clinuvel (ASX:CUV) secured regulatory approval from Health Canada to market its 16mg SCENESSE drug for adult patients with erythropoietic protoporphyria.
Mesoblast (ASX:MSB) reported a full-year net revenue of US$115 million following increased sales of its approved cellular medicine.
Sigma Healthcare (ASX:SIG) announced that co-founders Sam and Jack Gance may sell up to 20% of their combined $7.7 billion stake.
ReNerve (ASX:RNV) has secured a convertible note funding facility of up to $5 million to support its commercialisation strategy.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade